National Eye Institute (NEI)s

National Eye Institute (NEI)

48 Protocols (31 Active Accrual of new subjects, 17 Follow-up of previously enrolled subjects)


Active Accrual, Protocols Recruiting New Patients 
* 000519-EI:
Phase II, Multicenter, Open-label Safety Study of Bilateral NT-501 in Participants with Macular Telangiectasia Type 2

* 000187-EI:
Adaptive Optics Imaging of Outer Retinal Diseases

* 000078-EI:
Ocular Findings and Viral Persistence in Ocular Fluids in COVID-19 Survivors, a Natural History, Observational Study

* 20-EI-0163:
Oral Metformin for Treatment of ABCA4 Retinopathy

* 20-EI-0052:
A Phase I/IIa Trial for Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated with Age-Related Macular Degeneration

* 20-EI-0026:
An Observational Cross-Sectional Study of Virtual Reality Mobility Assessment of Functional Vision in Retinal Disease

* 20-EI-0004:
Adalimumab vs. Conventional Immunosuppression for Uveitis (ADVISE) Trial

* 19-EI-0056:
A Survey Study of Retinitis Pigmentosa (RP) Clinical Measures and Repeatability Testing of Potential Outcome Measures.

* 18-EI-0068:
An Investigation of Vitamin A Palmitate Supplementation in Patients with Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation

* 18-EI-0067:
An Investigation of Vitamin A Palmitate Supplementation in Patients with Age-Related Macular Degeneration (and without reticular pseudodrusen) and Delayed Dark Adaptation

* 18-EI-0046:
Perception, Sensation, Cognition and Action in Humans

* 17-EI-0112:
A Long-term Follow-up Study of Participants Enrolled in 11-EI-0147: Longitudinal Investigation of Dark Adaptation in Participants with Age-Related Macular Degeneration (DA_AMD)

* 17-EI-0071:
AMD Ryan Initiative Study

* 17-EI-0008:
The Natural History of Geographic Atrophy Associated with Age-Related Macular Degeneration

* 16-EI-0134:
Studies of the Natural History, Pathogenesis and Outcome of Ocular Disorders

* 16-EI-0104:
Clinical and Molecular Studies in Families with Inherited Eye Disease

* 16-EI-0090:
Natural History of Spinocerebellar Ataxia Type 7 (SCA7)

* 16-EI-0046:
Uveitis/Intraocular Inflammatory Disease Biobank (iBank)

* 16-EI-0024:
Rod and Cone Mediated Function in Retinal Disease

* 15-EI-0128:
The Genetics of Inherited Eye Disease

* 15-EI-0038:
A Phase I/IIa Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis

* 15-EI-0020:
Adaptive Optics Retinal Imaging

* 14-EI-0064:
Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions

* 13-EI-0049:
Pathogenesis and Genetics of Microphthalmia, Anophthalmia and Uveal Coloboma ( MAC)

* 12-EI-0042:
NEI Intramural Biorepository for Retinal Diseases

* 11-EI-0245:
Generation of Induced Pluripotent Stem (iPS) Cell Lines from Somatic Cells of Participants with Eye Diseases and from Somatic Cells of Matched Controls

* 11-EI-0147:
Longitudinal Investigation of Dark Adaptation in Participants with Age-Related Macular Degeneration

* 10-EI-0140:
Genotype - phenotype Study of Patients with Plaquenil-induced Retinal Toxicity, with Evaluation of the ABCA4 Gene

* 08-EI-0102:
Screening Protocol for the Evaluation and Diagnosis of Potential Research Participants

* 08-EI-0031:
Visual Motor Coordination

* 03-EI-0033:
X-Linked Juvenile Retinoschisis - Clinical and Molecular Studies

Active Follow-up, Protocols NOT Recruiting New Patients 

* 000108-EI:
An Observational Prospective Natural History Study of Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4

* 19-EI-0045:
A Sub-Study to the Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel) (NTMT-01/02E) to Provide the Renexus Implant to Participants Who Contributed a Single Eye Randomized to the Sham Procedure in the

* 18-EI-0142:
A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects with Active Non-Infectious Uveitis

* 18-EI-0055:
A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2

* 17-EI-0136:
Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)

* 16-EI-0169:
A Pilot Study to Investigate Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis

* 16-EI-0159:
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab

* 15-EI-0202:
Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated with Age-Related Macular Degeneration

* 14-EI-0171:
The Focal Electro-Oculogram in Macular Disease

* 13-EI-0072:
Microbiome and Ocular Inflammatory Disease

* 12-EI-0203:
Natural History of ABCA4-Related Retinopathies

* 11-EI-0264:
A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Central Retinal Vein Occlusions

* 11-EI-0263:
A Pilot Study for the Evaluation of Minocycline as a Microglia Inhibitor in the Treatment of Branch Retinal Vein Occlusions

* 08-EI-0043:
Age-Related Eye Disease Study (AREDS) and AREDS2 Follow-Up

* 07-EI-0213:
LI/NEI Repository

* 06-EI-0236:
National Ophthalmic Genotyping and Phenotyping Network Stage 1 - Creation of DNA Repository for Inherited Ophthalmic Diseases

* 06-EI-0068:
The Vitreous Proteome and Inflammatory Mediators in Ocular Inflammatory Disease

09/22/2021